Categories: CareCauseDrugLearnNewsProductScience
MucoLife Therapeutics develops innovative mucus modulators for COPD and Cystic Fibrosis, aiming to clear airways and improve breathing. Learn about our science and latest news.
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| 18.02.2025 | How a Swedish startup is transforming respiratory disease treatment | COPD affects 16 million in the US and 400 million globally and is the third leading cause of death.
A core problem in COPD, Cystic fibrosis (CF), asthma, and bronchiectasis, is the overproduction of thick, sticky mucus that obstructs and pl... |
Reviews 0
